Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine fibroids

Sunil Krishna Halder, Chakradhari Sharan, Omar Al-Hendy, Ayman Al-Hendy

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We examined the antitumor and therapeutic potentials of paricalcitol, an analog of 1,25-dihydroxyvitamin D3 with lower calcemic activity, against uterine fibroids using in vitro and in vivo evaluations in appropriate uterine fibroid cells and animal models. We found that paricalcitol has potential to reduce the proliferation of the immortalized human uterine fibroid cells. For the in vivo study, we generated subcutaneous tumors by injecting the Eker rat-derived uterine leiomyoma cell line (ELT-3) rat uterine fibroid-derived cell line in athymic nude mice supplemented with estrogen pellets. These mice were administered with vehicle versus paricalcitol (300 ng/kg/d) or 1,25-dihydroxyvitamin D3 (500 ng/kg/d) for 4 consecutive weeks, and the data were analyzed. We found that while both paricalcitol and 1,25-dihydroxyvitamin D3 significantly reduced fibroid tumor size, the shrinkage was slightly higher in the paricalcitol-treated group. Together, our results suggest that paricalcitol may be a potential candidate for effective, safe, and noninvasive medical treatment option for uterine fibroids.

Original languageEnglish (US)
Pages (from-to)1108-1119
Number of pages12
JournalReproductive Sciences
Volume21
Issue number9
DOIs
StatePublished - Jan 1 2014

Fingerprint

Calcitriol Receptors
Leiomyoma
Calcitriol
Neoplasms
Nude Mice
Cell Line
paricalcitol
Estrogens
Animal Models

Keywords

  • 1,25-dihydroxyvitamin D3
  • Zemplar
  • leiomyoma
  • paricalcitol
  • uterine fibroids
  • vitamin D3

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Medicine(all)

Cite this

Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine fibroids. / Halder, Sunil Krishna; Sharan, Chakradhari; Al-Hendy, Omar; Al-Hendy, Ayman.

In: Reproductive Sciences, Vol. 21, No. 9, 01.01.2014, p. 1108-1119.

Research output: Contribution to journalArticle

Halder, Sunil Krishna ; Sharan, Chakradhari ; Al-Hendy, Omar ; Al-Hendy, Ayman. / Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine fibroids. In: Reproductive Sciences. 2014 ; Vol. 21, No. 9. pp. 1108-1119.
@article{81a53eb7481b4b928450f870d23b0dc6,
title = "Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine fibroids",
abstract = "We examined the antitumor and therapeutic potentials of paricalcitol, an analog of 1,25-dihydroxyvitamin D3 with lower calcemic activity, against uterine fibroids using in vitro and in vivo evaluations in appropriate uterine fibroid cells and animal models. We found that paricalcitol has potential to reduce the proliferation of the immortalized human uterine fibroid cells. For the in vivo study, we generated subcutaneous tumors by injecting the Eker rat-derived uterine leiomyoma cell line (ELT-3) rat uterine fibroid-derived cell line in athymic nude mice supplemented with estrogen pellets. These mice were administered with vehicle versus paricalcitol (300 ng/kg/d) or 1,25-dihydroxyvitamin D3 (500 ng/kg/d) for 4 consecutive weeks, and the data were analyzed. We found that while both paricalcitol and 1,25-dihydroxyvitamin D3 significantly reduced fibroid tumor size, the shrinkage was slightly higher in the paricalcitol-treated group. Together, our results suggest that paricalcitol may be a potential candidate for effective, safe, and noninvasive medical treatment option for uterine fibroids.",
keywords = "1,25-dihydroxyvitamin D3, Zemplar, leiomyoma, paricalcitol, uterine fibroids, vitamin D3",
author = "Halder, {Sunil Krishna} and Chakradhari Sharan and Omar Al-Hendy and Ayman Al-Hendy",
year = "2014",
month = "1",
day = "1",
doi = "10.1177/1933719114537721",
language = "English (US)",
volume = "21",
pages = "1108--1119",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine fibroids

AU - Halder, Sunil Krishna

AU - Sharan, Chakradhari

AU - Al-Hendy, Omar

AU - Al-Hendy, Ayman

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We examined the antitumor and therapeutic potentials of paricalcitol, an analog of 1,25-dihydroxyvitamin D3 with lower calcemic activity, against uterine fibroids using in vitro and in vivo evaluations in appropriate uterine fibroid cells and animal models. We found that paricalcitol has potential to reduce the proliferation of the immortalized human uterine fibroid cells. For the in vivo study, we generated subcutaneous tumors by injecting the Eker rat-derived uterine leiomyoma cell line (ELT-3) rat uterine fibroid-derived cell line in athymic nude mice supplemented with estrogen pellets. These mice were administered with vehicle versus paricalcitol (300 ng/kg/d) or 1,25-dihydroxyvitamin D3 (500 ng/kg/d) for 4 consecutive weeks, and the data were analyzed. We found that while both paricalcitol and 1,25-dihydroxyvitamin D3 significantly reduced fibroid tumor size, the shrinkage was slightly higher in the paricalcitol-treated group. Together, our results suggest that paricalcitol may be a potential candidate for effective, safe, and noninvasive medical treatment option for uterine fibroids.

AB - We examined the antitumor and therapeutic potentials of paricalcitol, an analog of 1,25-dihydroxyvitamin D3 with lower calcemic activity, against uterine fibroids using in vitro and in vivo evaluations in appropriate uterine fibroid cells and animal models. We found that paricalcitol has potential to reduce the proliferation of the immortalized human uterine fibroid cells. For the in vivo study, we generated subcutaneous tumors by injecting the Eker rat-derived uterine leiomyoma cell line (ELT-3) rat uterine fibroid-derived cell line in athymic nude mice supplemented with estrogen pellets. These mice were administered with vehicle versus paricalcitol (300 ng/kg/d) or 1,25-dihydroxyvitamin D3 (500 ng/kg/d) for 4 consecutive weeks, and the data were analyzed. We found that while both paricalcitol and 1,25-dihydroxyvitamin D3 significantly reduced fibroid tumor size, the shrinkage was slightly higher in the paricalcitol-treated group. Together, our results suggest that paricalcitol may be a potential candidate for effective, safe, and noninvasive medical treatment option for uterine fibroids.

KW - 1,25-dihydroxyvitamin D3

KW - Zemplar

KW - leiomyoma

KW - paricalcitol

KW - uterine fibroids

KW - vitamin D3

UR - http://www.scopus.com/inward/record.url?scp=84907218622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907218622&partnerID=8YFLogxK

U2 - 10.1177/1933719114537721

DO - 10.1177/1933719114537721

M3 - Article

VL - 21

SP - 1108

EP - 1119

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 9

ER -